AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03336840
Drug: 1. Metformin tablets; 2. ProMetS probiotics powder
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Trial: NCT03176966
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 400 IU vitamin E nightly for 3 months.
Trial: NCT03176966
Drug: Ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will take 0.5mg ropinirole nightly for 3 months.
Trial: NCT02182037
Drug: Single rising doses of BIBT 1011 BS
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03761264
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
Trial: NCT01955460
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03002493
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate.
Trial: NCT03002493
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03002493
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
Trial: NCT02955186
Drug: Saracatinib
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saracatinib 125 mg once per day for 8 days
Trial: NCT03651882
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
Trial: NCT03651882
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin is given 0.1mg intravenously as a bolus after delivery.
Trial: NCT01088815
Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily
Trial: NCT02658162
Drug: SANGUINATE
RxNorm normalized name: Sanguinate
DrugBank: Pegylated carboxyhemoglobin (bovine) (DB17720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
Trial: NCT01899144
Drug: Albuterol Spiromax
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
Trial: NCT01899144
Drug: ProAir HFA
RxNorm normalized name: ProAir HFA
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
Trial: NCT03203564
Drug: Modufolin (arfolitixorin)
RxNorm normalized name: Modufolin
DrugBank: Modufolin (DB12676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
Trial: NCT01738139
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04648202
Drug: FS120
RxNorm normalized name: Fluticasone Salmeterol 120
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
Trial: NCT04810637
Drug: GX-I7
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human interleukin-7 hybrid Fc
Trial: NCT00751881
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet~Oral administration
Trial: NCT03049540
Drug: Tadalafil 20 MG
RxNorm normalized name: tadalafil 20 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
Trial: NCT01301612
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
Trial: NCT01301612
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
Trial: NCT01301612
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
Trial: NCT01566838
Drug: Subpleural pain catheter with infusion of 0.125% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
Trial: NCT03344328
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
Trial: NCT00024297
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04044547
Drug: Rotigotine, extended-release microspheres
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks.
Trial: NCT03088384
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
Trial: NCT00815841
Drug: METHYLPHENIDATE
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-20mg during one of the two sessions
Trial: NCT02460991
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01200121
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
Trial: NCT02835534
Drug: rhTNK-tPA
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Trial: NCT02835534
Drug: alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
Trial: NCT02546544
Drug: Linsitinib
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01318889
Drug: Dexpanthenol
RxNorm normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% dexpanthenol Mouth wash , three times a day, 10 cc each time
Trial: NCT03515980
Drug: BMS-986231
RxNorm normalized name: BMS-986231
DrugBank: Cimlanod (DB14983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration
Trial: NCT02985216
Drug: Lyrica
RxNorm normalized name: Lyrica
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
Trial: NCT00006348
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01821248
Drug: Gemcitabine, Cisplatin, S-1
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7
Trial: NCT00616239
Drug: 20-30% Salicylic Acid peels to the right side of the face
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
Trial: NCT00616239
Drug: 20-30% Salicylic Acid peels to the left side of the face
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
Trial: NCT02696512
Drug: Polypharmacy using FDA-approved products
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
Trial: NCT00370656
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: capsule, 150mg bd, 300mg bd
Trial: NCT00370656
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, 60mg on, 60mg bd
Trial: NCT00370656
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule. 25 mg bd, 25 mg om and 50 mg on
Trial: NCT00398528
Drug: Glatiramer acetate, (Copaxone®)
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03271255
Drug: Apatinib Mesylate Tablets
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
Trial: NCT03271255
Drug: Bevacizumab Injection
RxNorm normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
Trial: NCT00050713
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00266110
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
Trial: NCT03083158
Drug: Hepatitis B vaccine
RxNorm normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
Trial: NCT03170336
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
Trial: NCT02575794
Drug: Terameprocol
RxNorm normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01300286
Drug: RiaSTAP
RxNorm normalized name: RiaSTAP
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of 70 mg/kg will be administered intravenously.
Trial: NCT04510922
Drug: Droxidopa 100 MG [Northera]
RxNorm normalized name: droxidopa 100 MG [Northera]
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: droxidopa taken three times a day titrated up to a maximum of 600 mg.
Trial: NCT00631722
Drug: Quatiapine Fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600-750mg/day
Trial: NCT00631722
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-20mg/day
Trial: NCT02940886
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Trial: NCT01025713
Drug: GS-9411
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inhaled GS-9411
Trial: NCT02649686
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02649686
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00396604
Drug: indacaterol maleate
RxNorm normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03073603
Drug: Discontinuation of disease modifying therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who will discontinue their current MS drug. No other changes to their treatment occur.
Trial: NCT01391104
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
Trial: NCT01391104
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
Trial: NCT02413398
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
Trial: NCT02413398
Drug: Matching Placebo for Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
Trial: NCT00941239
Drug: metformin ER
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850mg daily for 30 days
Trial: NCT00941239
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850 mg daily for 30 days
Trial: NCT00861939
Drug: Bupropion HCI 300 mg Extended-Release Tablets EON
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03357718
Drug: Precedex
RxNorm normalized name: Precedex
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 µg/kg oral
Trial: NCT03357718
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mg/kg
Trial: NCT00591292
Drug: indibulin
RxNorm normalized name: Indibulin
DrugBank: Indibulin (DB06169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of indibulin given twice daily for up to 6 months
Trial: NCT03701555
Drug: Maximum Feasible Dose (MFD) of PvP002
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MFD of PvP002
Trial: NCT03701555
Drug: Maximum Tolerated Dose (MTD) of PvP001
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum Tolerated Dose (MTD) of PvP001
Trial: NCT03701555
Drug: MTD of PvP001 following 7 days of PPI treatment
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
Trial: NCT00646802
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
Trial: NCT01973790
Drug: Z-338
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg TID
Trial: NCT01748435
Drug: Qutenza
RxNorm normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single treatment with Qutenza
Trial: NCT01205685
Drug: OSI-906
RxNorm normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~* Dose level 2 = 150 mg twice a day~* Dose level 1 = 100 mg twice a day~* Dose level -1 = 100 mg twice a day~* Dose level -2 = 100 mg twice a day
Trial: NCT01205685
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the safety run phase of the study:~* Dose Level 2 = 100 mg/d~* Dose Level 1 = 100 mg/d~* Dose Level -1= 75 mg/d~* Dose Level -2 = 50 mg/d
Trial: NCT01205685
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In a pill form, by mouth, once per day at 2.5 mg/d.
Trial: NCT01205685
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
Trial: NCT03349710
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified day
Trial: NCT03349710
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified day